{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 1","description":"In part one of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the fenebrutinib trial and highlight the key takeaways that healthcare providers should be aware of.&amp;nbsp;&amp;nbsp; For more information, please read about the abstract that was presented at the&amp;nbsp;2026 AAN Annual Meeting.&amp;nbsp; Read more about the&amp;nbsp;Fenebrutinib Trial.&amp;nbsp; ","author_name":"Neurology Minute","author_url":"https:\/\/www.aan.com\/education-and-research\/online-learning-programs\/podcasts\/neurology-minute-podcast","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/42268680\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/45403e\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/42268680"}